Ivermectin Treatment for Covid-19.

To the Editor: Reis et al. (May 5 issue)(1) present the results of the TOGETHER platform trial, a large trial of ivermectin in outpatients with Covid-19. The relative risk of hospitalization or prolonged observation in the emergency department owing to Covid-19 (the primary outcome) in the ivermectin group as compared with the placebo group was 0.90 (95% Bayesian credible interval, 0.70 to 1.16), and the relative risk of death (a secondary outcome) was 0.88 (95% Bayesian credible interval, 0.49 to 1.55).(1) The prespecified threshold for the clinical utility of ivermectin was a 37.5% difference, as compared with placebo, in the . . .